Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. We have developed anti-ROBO1 CAR-NK cells that can target tumor cells highly expressing ROBO1. The purpose of this study is to evaluate the safety and effectiveness of cell therapy using ROBO1 CAR-NK cells to treat solid tumors.
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.
Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the diagnosis and treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK/T cell immunotherapy for malignant tumors.
100 项与 Asclepius (Hangzhou) Medical Technology Co., Ltd. 相关的临床结果
0 项与 Asclepius (Hangzhou) Medical Technology Co., Ltd. 相关的专利(医药)
100 项与 Asclepius (Hangzhou) Medical Technology Co., Ltd. 相关的药物交易
100 项与 Asclepius (Hangzhou) Medical Technology Co., Ltd. 相关的转化医学